Thursday, July 17, 2025
News

Subject Expert Committee gives nod to Covaxin for Phase 2, 3 trials on children aged 2 to 18 years

SocialTwist Tell-a-Friend    Print this Page   COMMENT

New Delhi | May 12, 2021 1:44:19 PM IST
The Subject Expert Committee (SEC) has given a nod to Bharat Biotech''s Covaxin for Phase 2 and 3 human clinical trials on children aged between two to eight years old, sources confirmed on Wednesday.

Covaxin is one of the two vaccines being manufactured in India at present and has been developed by Bharat Biotech in association with the Indian Council of Medical Research and the National Institute of Virology.

The firm on Tuesday informed that it has been supplying its COVID-19 vaccine directly to 18 states since May 1.

"Unflinching in our efforts, we will continue the steady supply of our vaccine," the company tweeted.

Maharashtra, Madhya Pradesh, Bihar, Uttar Pradesh, West Bengal and Assam are among the 18 states where the company has been supplying the vaccines directly.

Following the Government of India directives, the Hyderabad-based vaccine maker had earlier announced that it will provide Covaxin to state government hospitals at the rate of Rs 400 per dose. (ANI)

 
  LATEST COMMENTS (0)
POST YOUR COMMENT
Comments Not Available
 
POST YOUR COMMENT
 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
INDIA WORLD ASIA
'Where is fact-finding team of the BJP?'...
Assam Minister discusses issues concerni...
Couple facing financial duress die by su...
Odisha observes bandh over Balasore stud...
Manipur's indigenous Haofa dog breed fin...
CM Nitish Kumar announces free electrici...
More...    
 
 Top Stories
Nepal's southern plain go dry mid-m... 
Urban consumers turn value-seeker w... 
Parliament panel reviews UIDAI func... 
EAM Jaishankar meets South Korean s... 
Rewari Rising: The Promise of Affor... 
Sent strong message to world that t... 
"Golden day:" Bihar DyCM Samrat Cho... 
Bangladesh forms a committee to inv...